Ma H C, Dohi S, Wang Y F, Ishizawa Y, Yanagidate F
Department of Anesthesiology and Critical Care Medicine, Gifu University School of Medicine, Tsukasamachi-40, Gifu City, Gifu 500-8705, Japan.
Anesth Analg. 2001 May;92(5):1307-15. doi: 10.1097/00000539-200105000-00043.
To clarify the supraspinal and spinal actions of a cholinergic agonist, carbachol, and an opioid, oxycodone, we studied their antinociceptive and behavioral effects when administered into brainstem medial pontine reticular formation (mPRF) or spinal subarachnoid space with or without pretreatment of muscarinic receptor subtype antagonist. Sprague-Dawley rats were implanted with a 24-gauge stainless steel guide cannula into the mPRF and chronically implanted with a lumbar intrathecal catheter. Antinociception was tested using tail flick latency, motor coordination was evaluated by the rotarod test, and overt sedation was assessed using a behavioral checklist. Carbachol (0.5-4.0 microg) administered into the mPRF produced significant dose- and time-dependent antinociception, sedation, and motor dysfunction. These were completely blocked by pretreatment with atropine and the M(2) muscarinic antagonist, methoctramine, and partially blocked by pretreatment with M(1) pirenzepine but not with M(3) p-fHHSID: Oxycodone administered into the mPRF did not produce such effects. Spinal carbachol and oxycodone produced antinociception without any behavioral effects; their antinociceptive effects were completely blocked by pretreatment with atropine and M(2) antagonist. These results suggest that the antinociceptive action of carbachol is mediated by muscarinic cholinergic receptor activation, especially by M(2) receptor subtype in mPRF and spinal cord, and that although oxycodone seems unlikely to affect the cholinergic transmission of mPRF, spinal oxycodone-induced analgesia is at least partly mediated via the activation of M(2) receptor subtype at the spinal cord.
Carbachol-induced antinociception and sedation is mediated with the activation of M(2) muscarinic receptors. Oxycodone administered into brainstem medial pontine reticular formation did not cause any antinociceptive or behavioral effects, but its spinal administration produced a significant antinociception via M(2) muscarinic receptor activation
为阐明胆碱能激动剂卡巴胆碱和阿片类药物羟考酮的脊髓上和脊髓作用,我们研究了将它们注入脑桥内侧网状结构(mPRF)或脊髓蛛网膜下腔时,在有或没有毒蕈碱受体亚型拮抗剂预处理的情况下,它们的抗伤害感受和行为效应。将24号不锈钢引导套管植入Sprague-Dawley大鼠的mPRF,并长期植入腰段鞘内导管。使用甩尾潜伏期测试抗伤害感受,通过转棒试验评估运动协调性,并使用行为检查表评估明显的镇静作用。注入mPRF的卡巴胆碱(0.5 - 4.0微克)产生显著的剂量和时间依赖性抗伤害感受、镇静和运动功能障碍。这些作用被阿托品和M(2)毒蕈碱拮抗剂美索曲明预处理完全阻断,被M(1)哌仑西平预处理部分阻断,但未被M(3) 4-氟己基六氢哒嗪预处理阻断。注入mPRF的羟考酮未产生此类效应。脊髓注射卡巴胆碱和羟考酮产生抗伤害感受但无任何行为效应;它们的抗伤害感受作用被阿托品和M(2)拮抗剂预处理完全阻断。这些结果表明,卡巴胆碱的抗伤害感受作用是由毒蕈碱胆碱能受体激活介导的,特别是通过mPRF和脊髓中的M(2)受体亚型,并且尽管羟考酮似乎不太可能影响mPRF的胆碱能传递,但脊髓注射羟考酮诱导的镇痛至少部分是通过脊髓中M(2)受体亚型的激活介导的。
卡巴胆碱诱导的抗伤害感受和镇静是由M(2)毒蕈碱受体激活介导的。注入脑桥内侧网状结构的羟考酮未引起任何抗伤害感受或行为效应,但其脊髓给药通过M(2)毒蕈碱受体激活产生显著的抗伤害感受。